Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Schott Pharma Invests €100M in New Sterile Cartridge Facility in Hungary

Schott Pharma, a leading manufacturer of pharmaceutical packaging and delivery systems, has announced a significant expansion of its manufacturing capabilities in Hungary. The company is investing over €100 million ($115 million) to construct a new facility dedicated to the production of sterile ready-to-use (RTU) cartridges at its site in Lukácsháza.

NoahAI News6/5/2025

HHS Staffers Sue Over Mass Layoffs Amid Controversial Federal Workforce Reduction

Former employees of the U.S. Department of Health and Human Services (HHS) have filed a lawsuit against the Trump administration, alleging illegal termination of thousands of workers based on inaccurate personnel records. The lawsuit, which seeks class-action status, was filed on Tuesday in a Washington D.C. district court and targets HHS, the Department of Government Efficiency, and other agencies involved in the recent federal workforce reduction initiative.

NoahAI News6/5/2025

RegenXBio's DMD Gene Therapy Shows Promise in Phase 1/2 Trial

RegenXBio, a biotechnology company focused on developing gene therapies, has released updated data from its phase 1/2 trial of RGX-202, a potential treatment for Duchenne muscular dystrophy (DMD). The results demonstrate improved functional outcomes in older boys with the disease, positioning the company as a strong competitor in the race to bring effective DMD treatments to market.

NoahAI News6/5/2025

Corcept's ALS Drug Shows Promise in Survival Data Despite Phase 2 Failure

Corcept Therapeutics has unveiled promising survival data from its previously failed phase 2 trial for amyotrophic lateral sclerosis (ALS), potentially breathing new life into the development of dazucorilant. The company presented these findings at the European Network to Cure ALS 2025 annual meeting, shedding light on the drug's potential benefits despite its initial setback.

NoahAI News6/5/2025

Cullinan Therapeutics Expands Autoimmune Portfolio with $700M BCMA Bispecific Deal

Cullinan Therapeutics has significantly bolstered its autoimmune disease pipeline through a $700 million licensing agreement with Genrix Bio for velinotamig, a BCMAxCD3 bispecific T cell engager. The deal, announced on June 4, 2025, marks a strategic expansion of Cullinan's autoimmune program and complements its existing CD19xCD3 T-cell engager, CLN-978.

NoahAI News6/5/2025

FDA Grants Sarepta Therapeutics Novel Platform Technology Designation for Gene Therapy

The U.S. Food and Drug Administration (FDA) has awarded Sarepta Therapeutics a groundbreaking "platform technology designation" for its gene therapy delivery tool, potentially accelerating the review process for future gene therapy applications. This development marks a significant milestone in the FDA's efforts to streamline the evaluation of genetic medicines, particularly those targeting rare diseases.

NoahAI News6/5/2025

Daiichi Sankyo's ADC Success and Future Challenges Under New CEO Hiroyuki Okuzawa

Daiichi Sankyo, a leading Japanese pharmaceutical company, continues to make waves in the oncology field with its antibody-drug conjugate (ADC) technology. As the company's new CEO, Hiroyuki Okuzawa, takes the helm, he faces the challenging task of maintaining Daiichi Sankyo's momentum and charting a course for future growth.

NoahAI News6/5/2025

Bispecific Antibodies and Breast Cancer Treatments Headline ASCO 2025, Amid Funding Concerns

The American Society of Clinical Oncology's (ASCO) 2025 annual meeting showcased groundbreaking advancements in cancer treatment, particularly in breast cancer therapies and bispecific antibodies. However, these promising developments were overshadowed by growing concerns over potential cuts to U.S. science funding.

NoahAI News6/5/2025

Neuralink Secures $650M in Series E Funding, Expands Clinical Trials for Brain-Computer Interface Technology

Elon Musk's brain-computer interface startup, Neuralink, has announced a significant milestone in its quest to revolutionize human-machine interaction. The company has successfully closed a $650 million Series E funding round, attracting investments from prominent backers including ARK Invest, Founders Fund, and Sequoia Capital.

NoahAI News6/5/2025

Layoffs and Restructuring Continue to Reshape Biopharma Landscape

The biopharmaceutical industry continues to face headwinds in 2025, with numerous companies announcing layoffs and restructuring efforts aimed at reducing costs and extending cash runways. From large pharmaceutical giants to small biotechs, the trend of workforce reductions shows no signs of abating as firms grapple with pipeline setbacks, changing market dynamics, and financial pressures.

NoahAI News6/5/2025

Vigil's TREM2 Antibody Fails Phase II Trial, Sanofi Acquisition Unaffected

Vigil Neuroscience's monoclonal antibody iluzanebart has failed to meet its primary endpoints in a Phase II clinical trial for a rare brain disorder, prompting the discontinuation of its development. This setback comes just two weeks after Vigil agreed to a $470 million buyout deal with pharmaceutical giant Sanofi.

NoahAI News6/5/2025

Eli Lilly Inks $870M Deal with Camurus for Long-Acting Obesity and Diabetes Drugs

Eli Lilly has entered into a licensing agreement with Swedish biotechnology firm Camurus, potentially worth up to $870 million, to develop long-acting versions of its obesity and diabetes medications. The collaboration aims to extend Lilly's dominance in the rapidly growing cardiometabolic health market by leveraging Camurus' FluidCrystal technology to create injectable treatments with extended durability.

NoahAI News6/5/2025

«1...56 57 58...67 »